Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
life sciences
national blog main
national top stories
novartis
5
×
san francisco top stories
5
×
boston blog main
boston top stories
fda
indiana blog main
indiana top stories
national
new york top stories
san francisco blog main
biogen
boulder/denver blog main
boulder/denver top stories
clinical trials
detroit blog main
detroit top stories
eli lilly
europe top stories
genentech
new york blog main
raleigh-durham blog main
raleigh-durham top stories
san diego blog main
san diego top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
amgen
cancer
europe blog main
gene therapy
ipo
roche
What
fda
5
×
drug
medicines
new
approval
bio
roundup
therapy
won
activity
address
amgen
approvals
approved
approves
atrophy
august
biogen
biotech
blueprint
busy
cancer
candidates
carries
certain
clamped
class
covid
daily
days
decisions
delays
designed
developed
developing
devices
drugs
economic
evrysdi
fast
Language
unset
Current search:
novartis
×
fda
×
" san francisco top stories "
×
@xconomy.com
3 years ago
FDA Approves Blueprint Cancer Drug Targeting RET Genetic Signatures
@xconomy.com
3 years ago
FDA Green-Lights Roche Spinal Muscular Atrophy Drug, First Oral Therapy
@xconomy.com
4 years ago
Bio Roundup: Fast FDA Approvals, Biogen Delays, ORIC’s IPO & More
@xconomy.com
4 years ago
Bio Roundup: Sarepta’s Stumble, Opioid Suits, Shkreli’s Legacy & More
@xconomy.com
5 years ago
Amgen Migraine Drug Gets FDA Nod, First in New Class of Medicines